ClinicalTrials.gg
CompletedNCT05586711Updated Dec 17, 2024

Local DHEA and Estradiol on Dyspareunia in Postmenopausal Women

A Phase 4 interventional study of vaginal estradiol 10 μg and vaginal DHEA 6.5 mg in Vulvovaginal Atrophy and Genitourinary Syndrome of Menopause, sponsored by Angelica Lindén Hirschberg. Completed at 1 site in Sweden. Open to female participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-12-17.

Sponsored by Angelica Lindén Hirschberg · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 9 months after the study started (first participant enrolled Dec 2020, registered Oct 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
170
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
Female
01

Study summary

Vulvovaginal atrophy (VVA) is a condition characterized by vaginal dryness, itching, burning, irritation and dyspareunia. The condition is mainly due to estrogen deficiency and is common during and after menopause. Furthermore, androgens may have an important function in these symptoms. The purpose of the study is to compare vaginal estrogen with vaginal dehydroepiandrosterone (DHEA, an androgen precursor) on dyspareunia (primary outcome), a symptom of VVA in postmenopausal women. Secondary outcomes are total symptom score of VVA (vaginal dryness, irritation/itching, maturation index, pH), clinical signs of VVA, sexual function, urogenital symptoms, vaginal histomorphology, sex hormone levels and short-term safety. The hypothesis of the study is that the treatments will have a similar effect on dyspareunia while DHEA, through local androgenic effects (eg growth of muscle tissue and nerve density in the vaginal wall), may be more effective in treating other related symptoms such as sexual dysfunction. 170 postmenopausal women will be randomly assigned to treatment with either vaginal estrogen (Vagifem) or vaginal DHEA (Intrarosa). The women are examined at the start of the study, after 4 weeks of daily application and after another 8 weeks of treatment with twice a week application of the vaginal treatment. The study is expected to provide increased knowledge about the effect of the treatments of VVA in postmenopausal women as well as whether vaginal DHEA has additional positive effects on sexual function compared to vaginal estrogen.

02

Conditions studied

  • Vulvovaginal Atrophy
  • Genitourinary Syndrome of Menopause

Keywords

  • Vulvovaginal atrophy
  • Genitourinary Syndrome of Menopause
03

In context

Lead sponsor

Angelica Lindén Hirschberg is the lead sponsor of 4 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • women (non-hysterectomized or hysterectomized) must satisfy either: a) No menses for at least one year for non-hysterectomized women, or b) Follicle stimulating hormone (FSH) levels >40 IU/L
  • Women who have self-identified at screening and baseline (Day 1) as experiencing moderate to severe dyspareunia, using VASQ questionnaire (section 1)
  • Between 40 and 80 years of age
  • (BMI) 19-35
  • Women having a vaginal pH above 5 at screening and baseline (Day 1)
  • Women who currently have intercourse or other sexual activity, at least once a month, with a partner
  • Normal mammogram within 12 months (of Day 1)
  • A normal PAP smear (which includes inflammatory changes) within the last 12 months (of Day 1) for both non-hysterectomized and hysterectomized women.
  • Understands Swedish and is willing to participate in the study and sign an

Exclusion criteria

Exclusion Criteria:

  • Undiagnosed abnormal vaginal bleeding
  • Previous diagnosis of cancer, except skin cancer (non-melanoma)
  • Lichen Sclerosis and other pathological conditions in vulva and/or vagina
  • Active or history of thromboembolic disease
  • metabolic or endocrine disease (including diabetes mellitus) not controlled by medication
  • Oral estrogen, progestin or DHEA exposure or intrauterine progestin therapy in the 8 weeks prior to baseline assessments (screening visit)
  • Vaginal hormonal products (rings, creams, gels or tablets) or transdermal estrogen alone or estrogen/progestin products in the 4 weeks prior to baseline assessments (screening visit)
  • Use of testosterone or other anabolic steroid within 6 months prior to screening visit
  • Natural oral estrogenic products in the 4 weeks prior to baseline assessments
  • Confirmed clinically significant depression (not controlled by standard therapy) or confirmed history of severe psychiatric disturbance
  • The administration of any drug within 30 days of screening visit
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
170 participants (actual)

Study arms

  • Active comparator
    Vaginal estradiol 10 μg

    Drug: vaginal estradiol 10 μg

  • Active comparator
    Vaginal DHEA 6,5 mg

    Drug: vaginal DHEA 6.5 mg

Interventions

06

What researchers measure

Primary outcomes

  1. Dyspareunia, a symptom of VVA in postmenopausal women

    Patient reports in the Vaginal Atrophy Symptoms Questionnaire (VASQ, section 1). A 4-point scale, where a higher point means more symptoms.

    Time frame: Primary endpoint will be evaluated as change in dyspareunia (VASQ section 1) from baseline to Week 12

Secondary outcomes

  1. Total symptom score of VVA

    Vaginal dryness and irritation/itching (VASQ, section 2 and 3, a 4-point scale, where a higher point means more symptoms)

    Time frame: Change from baseline to Week 4 and 12

  2. Clinical signs of VVA

    Examination of vaginal atrophy symptoms (VAX). A 4-point scale, where a higher point means more symptoms.

    Time frame: Change from baseline to Week 4 and 12

  3. Sexual function

    Profile of Female Sexual Function (PFSF) and its seven domains desire, arousal, orgasm, pleasure, concern, responsiveness and self-image (range from 0 to 100, where a lower score means more dysfunction)

    Time frame: Change from baseline to Week 4 and 12

  4. Urinary incontinence

    The Incontinence Impact Questionnaire (IIQ-7, a 4-point scale, where a higher point means more symptoms)

    Time frame: Change from baseline to Week 4 and 12

  5. Histomorphology of the vaginal wall

    Histomorphology (thickness of epithelium, lamina propria and muscle layer in vaginal biopsies)

    Time frame: Change from baseline to Week 4 and 12

  6. Sex hormone levels

    Sex hormone levels (estradiol and testosterone)

    Time frame: Change from baseline to Week 4 and 12

Other outcomes

  1. Sexual activity

    Sexual activity log (SAL, the number of satisfying sexual episodes over a 1-week period)

    Time frame: Change from baseline to Week 4 and 12

  2. Sexual distress

    the Personal Distress Scale (PDS, 0 \[no distress\] to 100 \[maximum distress\]).

    Time frame: Change from baseline to Week 4 and 12

  3. Urogenital distress

    Urogenital Distress Inventory (UDI-6, a 4-point scale, where a higher point means more symptoms)

    Time frame: Change from baseline to Week 4 and 12

07

Study locations

1 site
  • Karolinska University Hospital
    Stockholm, 171 76, Sweden
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2020 to primary completion in Dec 2024, 47 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2022
First posted
Oct 19, 2022
StartActual
Dec 18, 2020
Primary completionActual
Dec 15, 2024
CompletionActual
Dec 15, 2024
Last update
Dec 17, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 17, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05586711
Lead sponsor
Angelica Lindén Hirschberg
Responsible party
Angelica Lindén Hirschberg (Professor, MD, PhD, Karolinska University Hospital) — Sponsor-investigator
First posted
Oct 19, 2022
Start date
Dec 18, 2020
Primary completion
Dec 15, 2024
Completion
Dec 15, 2024
Last update
Dec 17, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Estradiol · Dehydroepiandrosterone

Start the discussion